TY - JOUR
T1 - HLA pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the Greater Middle East
AU - Masmoudi, Hend Chaker
AU - Afify, Nariman
AU - Alnaqbi, Halima
AU - Alhalwachi, Zainab
AU - Tay, Guan K.
AU - Alsafar, Habiba
PY - 2022/8/1
Y1 - 2022/8/1
N2 - Specific HLA associations with drug hypersensitivity may vary between geographic regions and ethnic groups. There are little to no data related to HLA-drug hypersensitivity on populations who reside in the Greater Middle East (GME), a vast region spanning from Morocco in the west to Pakistan in the east. In this review, the authors intended to summarize the significant HLA alleles associated with hypersensitive drug reactions induced by different drugs, as have been found in different populations, and to summarize the prevalence of these alleles in the specific and diverse populations of the GME. For example, HLA-B*57:01 allele prevalence, associated with abacavir-induced hypersensitivity, ranges from 1% to 3%, and HLA-DPB1*03:01 prevalence, associated with aspirin-induced asthma, ranges from 10% to 14% in the GME population. Studying pharmacogenomic associations in the ethnic groups of the GME may allow the discovery of new associations, confirm ones found with a low evidence rate and enable cost-effectiveness analysis of allele screening before drug use.
AB - Specific HLA associations with drug hypersensitivity may vary between geographic regions and ethnic groups. There are little to no data related to HLA-drug hypersensitivity on populations who reside in the Greater Middle East (GME), a vast region spanning from Morocco in the west to Pakistan in the east. In this review, the authors intended to summarize the significant HLA alleles associated with hypersensitive drug reactions induced by different drugs, as have been found in different populations, and to summarize the prevalence of these alleles in the specific and diverse populations of the GME. For example, HLA-B*57:01 allele prevalence, associated with abacavir-induced hypersensitivity, ranges from 1% to 3%, and HLA-DPB1*03:01 prevalence, associated with aspirin-induced asthma, ranges from 10% to 14% in the GME population. Studying pharmacogenomic associations in the ethnic groups of the GME may allow the discovery of new associations, confirm ones found with a low evidence rate and enable cost-effectiveness analysis of allele screening before drug use.
KW - adverse drug reactions
KW - drug hypersensitivity
KW - Greater Middle East
KW - HLA pharmacogenomic associations
KW - HLA polymorphism
UR - http://www.scopus.com/inward/record.url?scp=85137135157&partnerID=8YFLogxK
U2 - 10.2217/pgs-2022-0078
DO - 10.2217/pgs-2022-0078
M3 - Review article
C2 - 35971864
AN - SCOPUS:85137135157
SN - 1462-2416
VL - 23
SP - 695
EP - 708
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 12
ER -